|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Aerovate Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Aerovate Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
7-2-2021 Insider Buy |
Asset Management, LP Cormorant
|
$14.00
CAGR »
|
$7,000,000.00 500,000 shares |
7-2-2021 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. Director and >10% Owner |
$14.00
CAGR »
|
$38,999,996.00 2,785,714 shares |
7-2-2021 Insider Buy |
Sofinnova Venture Partners X, L.P. >10% Owner |
$14.00
CAGR »
|
$4,999,988.00 357,142 shares |
7-2-2021 Insider Buy |
Maha Katabi Director and >10% Owner |
$14.00
CAGR »
|
$4,999,988.00 357,142 shares |
7-2-2021 Insider Buy |
David S. Grayzel Director |
$14.00
CAGR »
|
$7,499,996.00 535,714 shares |
7-2-2021 Insider Buy |
Atlas Venture Fund XII, L.P. >10% Owner |
$14.00
CAGR »
|
$7,499,996.00 535,714 shares |
Also See: Institutional Holders of AVTE
Also See: SEC filings
Below we present the annualized performance delivered by Aerovate Therapeutics stock since 7-2-2021 (the date of the most recent
insider purchase). The performance of the investment from the time Aerovate Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about AVTE being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/06/2021 |
|
End date: |
05/10/2024 |
|
Start price/share: |
$18.87 |
|
End price/share: |
$19.83 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
5.09% |
|
Average Annual Total Return: |
1.76% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,509.18 |
|
Years: |
2.85 |
|
Aerovate Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Aerovate Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding AVTE
|
|